11 trials newly registered in Immune System Diseases, first posted 2026-10-21, by therapeutic area, largest first. All areas.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN) | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 100 | 2026-10-15 | 2026-10-21 |
| Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease ETHY-001, Placebo - Thyroid Eye Disease (TED), Graves' Disease | Phase 1 | Recruiting | Ethyreal Bio, Inc. | 72 | 2026-07-06 | 2026-10-21 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH) Placebo, LAM-001 - Sarcoidosis Associated Pulmonary Hypertension | Phase 2 | Not yet recruiting | IRulya Therapeutics Inc. | 60 | 2026-12-01 | 2026-10-21 |
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies abrocitinib - Dermatitis, Atopic | Not yet recruiting | Pfizer | 120 | 2026-10-01 | 2026-10-21 | |
| Comprehensive Intervention to Promote Adjustment in Adolescents With Type 1 Diabetes and Their Parents During Transfer of Health Care Responsibility CONEXIÓN ADAPTAR - DM1, Usual Care - Type 1 Diabetes Mellitus (T1DM), Parent | Not applicable | Completed | Universidad de la Sabana | 34 | 2025-03-01 | 2026-10-21 |
| Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus Isoimmunization Intrauterine Transfusion, Intravenous immunoglobulin (IVIG) - Hemolytic Disease of the Newborn, Fetal Anemia | Phase 2 | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 30 | 2026-05-25 | 2026-10-21 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study of Multiple Ascending Doses of EB070 Injection in Adults With Moderate-to-Severe Asthma EB070 - Asthma | Phase 1 | Not yet recruiting | Biotech Pharmaceutical Co., Ltd. | 20 | 2026-09-30 | 2026-10-21 |